key: cord-0744834-68gvgbck
authors: Warren, Graham; Adjei, Alex A.
title: A CALL FOR RAPID SUBMISSION OF DATA FOR AGGREGATE REVIEW: Can daily radiotherapy imaging be used as a potential screen for COVID-19?
date: 2020-04-21
journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
DOI: 10.1016/j.jtho.2020.04.006
sha: 4e01a6a2ea3f1d911168135e6e92de98cc8e548c
doc_id: 744834
cord_uid: 68gvgbck

nan

The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an ongoing pandemic that is increasingly changing society and medical care as a whole. The general population is becoming more subject to contact restrictions and clinical providers are now faced with trying to adapt clinical care patterns to the risk of COVID-19. Exemplifying careful consideration of how cancer care and COVID-19 interact, Suppli et al. and McGinnis et al. present very interesting, timely, and potentially impactful case reports exemplifying how some care patterns may need to change during this pandemic.

Suppli et al. present the case of a new COVID-19 diagnosis in a patient during radiotherapy (1). The patient was a 74 year old male receiving treatment with concurrent chemoradiotherapy for Stage III non-small cell lung cancer (NSCLC). Within the first 2 weeks of treatment, the patient developed COVID-like symptoms of fever, cough, fatigue, and myalgia. Unfortunately, infection with the SARS-CoV 2 virus was confirmed, the patient's symptoms progressed, and he ultimately passed away from COVID-19. In a parallel report by McGinnis et al., a 63 year old female with recurrent lung cancer was being treated with stereotactic ablative radiotherapy (SABR), also commonly referred to as stereotactic body radiotherapy (SBRT). The patient was screened for COVID-19 symptoms with no presenting signs of infection. However, in both cases, review of image guidance scans supported infection.

As a part of standard radiotherapy (RT) to ensure accurate treatment for conventional RT or SABR/SBRT, patients commonly receive daily computed tomography (CT) scans of the chest. While image guidance CT scans may not have diagnostic quality of conventional CT scans from radiology departments, CT scans during RT provide sufficient detail to accurately align patients for daily RT and show sufficient detail to see mild to severe pulmonary opacification, atelectasis, effusions, and fiducial markers used to guide treatment. Review of daily imaging by Suppli et al. revealed multiple new pulmonary infiltrates between CT on day 7 and 8. Importantly, infiltrates were noted 36 hours prior to symptoms, but the interval between sequential CBCTs was 3 days over the weekend. The case report by McGinnis et al. demonstrated new bilateral ground glass opacities after a 20 day interval, but in a patient that was ultimately asymptomatic and required at home observation. For Suppli et al., patient symptoms were used to guide COVID-19 screening and scans were retrospectively reviewed after COVID-19 was confirmed. In contrast, McGinnis et al. noted changes on CT scans that then prompted COVID-19 testing. In both cases, authors proposed the utility of CBCTs for potential early detection.

Findings from both case reports exemplify how careful consideration and review of patient factors could be useful to aid in the diagnosis and management of patients during the COVID-19 pandemic. While it is critical to note that these reports are in just 2 pateitns, it also presents the opportunity for oncologists, and radiation oncologists in particular, to revise daily review of patient treatment. For most radiation oncologists who review daily CBCTs for localization, it can be very easy and quick to review images for new spotty pulmonary infiltrates or ground glass opacities during RT. This is by no means diagnostic at this time and infiltrates could represent other causes of infection or chemotherapy associated pneumonitis. However, infiltrates associated with radiation pneumonitis typically occur weeks to months after completion of RT. New infiltrates that develop from one day to the next or between subsequent treatments during RT are worthy of investigation. Because infiltrates between sequential CTs developed between Friday and Monday for Suppli et al., there is a possibility that new infiltrates could have been noted more than 36 hours prior to the onset of symptoms. The interval of 20 days reported by McGinnis et al. does not help narrow the window of observation. However, it is important to note that changes were observed in both a patient that was asymptomatic as well as a patient who developed severe disease and died. This suggests that new findings on image guided CT scans during RT could be useful to assist in COVID-19 screening and detection.

These case reports are limited by all of the standard issues associated with single patient case reports including random chance. More data are needed to clarify the clinical utility of these observations. However, in line with suggestions by Suppli ] However, the primary objective of this request is to rapidly determine if there is correlation between the onset of new pulmonary infiltrates observed during RT and COVID-19. It is not expected that analyses will be delayed for optional items once sufficient data has been aggregated to review for correlation. Analyses and authorship will be shared for all contributors who submit data.

Early appearance of COVID-19 associated pulmonary infiltrates during daily radiotherapy imaging for lung cancer

Rapid detection of asymptomatic COVID-19 by CT image-guidance for stereotactic ablative radiotherapy